Brainstorm Cell Therapeutics Inc. (BCLI)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Brainstorm Cell Therapeutics Inc. (BCLI) is up 43.2% since the beginning of the year. At $1 per share, BCLI is trading 40.5% below its 52-week high of $1. Investors who bought $1,000 worth of BCLI shares 5 years ago would now be looking at an investment worth $15.

Brainstorm Cell Therapeutics Inc. (BCLI) has returned 43.17% so far this year and -26.69% over the past 12 months. Over the last ten years, BCLI has returned -31.67% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Aug 28, 2003, BCLI's average daily return is +0.14%, while the average monthly return is +1.92%. At this rate, an investment would double in approximately 3.0 years.

Historically, 43% of months were positive and 57% were negative. The best month was Jan 2009 with a return of +166.7%, while the worst month was Sep 2023 at -88.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.

On a daily basis, BCLI closed higher 38% of trading days. The best single day was Aug 24, 2009 with a return of +150.0%, while the worst single day was Nov 17, 2020 at -66.3%.

Brainstorm Cell Therapeutics Inc. has an annualized alpha of 37.18%, beta of 0.38, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since August 29, 2003.

• This stock participated in 133.28% of S&P 500 Index downside but only 9.27% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.38 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BCLI ranks 28 for risk / return — below 28% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Brainstorm Cell Therapeutics Inc. (BCLI) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Brainstorm Cell Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Brainstorm Cell Therapeutics Inc. was 99.94%, occurring on Feb 17, 2026. The portfolio has not yet recovered.

The current Brainstorm Cell Therapeutics Inc. drawdown is 99.90%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Brainstorm Cell Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Brainstorm Cell Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.